What: Shares of Array BioPharma, a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from ...
What: Shares of Array BioPharma, a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after ...
Array BioPharma Inc. of Boulder, Colo., and Celgene Corporation, a Summit-based biopharmaceutical company, have announced a research and development collaboration on the discovery, development and ...
When it comes to buying an experienced cancer drug specialist, a bidding war is naturally expected. But in the case of Pfizer’s $11 billion deal for Array BioPharma, that didn’t happen. Still, it didn ...
NEW YORK (AP) — Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline ...
Shares of Array BioPharma (NASDAQ: ARRY) , Deciphera Pharmaceuticals (NASDAQ: DCPH) , and Blueprint Medicines (NASDAQ: BPMC) rose as much as 14%, 19%, and 16%, respectively, in early morning trading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results